AstraZeneca Pharma India Ltd

BSE: 506820

23

total announcements

ASTRAZEN.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 20 Oct 2026

Market Cap

₹15,108 Cr

P/E (TTM)

89.1

EPS (TTM)

₹67.85

52W Low

₹5,660.00

52W High

₹9,850.00

Dividend Yield

0.60%

Beta

0.23

Price / Book

17.3

Debt / Equity

12.7

Revenue (TTM)

₹2,432 Cr

Gross Margin

36.83%

Operating Margin

6.40%

AnnouncementsDiscussion
BSEAGM/EGMMgmt Change4d ago

AstraZeneca Pharma India Ltd

Please find the enclosed letter of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd. has announced the outcome of its postal ballot, where two resolutions were passed with requisite majority. The first resolution approved the appointment of Mr. Arun Krishna as a Non-Executive Director, and the second resolution changed the designation of Ms. Bhavana Agrawal from Executive Director to Non-Executive Director.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change15 Sept 2026

ASTRAZENECA PHARMA INDIA LIMITED

ASTRAZENECA PHARMA INDIA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" >&nbsp;</td><td class="TTRow_left"><b>&nbsp;Details</b></td></tr> <tr><td ....

AstraZeneca Pharma India Limited has informed the BSE about the cessation of a director, Medical Affairs, Biopharmaceutical Business Unit, and Rare Disease Business Unit.

Read more →
BSECompany UpdateMgmt Change15 Sept 2026

ASTRAZENECA PHARMA INDIA LIMITED

ASTRAZENECA PHARMA INDIA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.<p><b>Details are as under:</b></p> <table width="100%" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td bgcolor="#d6d6d6"><table border="0" cellpadding="4" cellspacing="1" width="100%"> <tbody> <tr><td width="250" class="TTRow_left" >&nbsp;</td><td class="TTRow_left"><b>&nbsp;Details</b></td></tr> <tr><td ....

AstraZeneca Pharma India Limited has informed the BSE about the cessation of a director, specifically the Director - Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit.

Read more →
BSECompany UpdateRegulatory25 Aug 2026

AstraZeneca Pharma India Ltd

Please find the enclosed document of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd has received a stay order from the Hon'ble High Court of Delhi on the Demand Notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013. The stay is until February 10, 2027, subject to the company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General of the Court.

Read more →📎 1 attachment
BSEAGM/EGMResults10 Aug 2026

AstraZeneca Pharma India Ltd

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd announced the outcome of its 47th Annual General Meeting (AGM) held on August 10, 2026. The AGM adopted the financial statements for the year ended March 31, 2026, declared a dividend of Rs. 36/- per equity share, and appointed new auditors and an independent director. The company also provided remote e-Voting facility to members.

Read more →📎 1 attachment
BSEResult▲ PositiveResults10 Aug 2026

AstraZeneca Pharma India Ltd

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd has announced its Q1 FY2026-27 financial results, reporting a 30% growth in total revenue from operations to INR 6,828 Mn, driven by continued momentum across its core therapy areas. The company has also received regulatory approvals for several new treatments, including acalabrutinib and trastuzumab deruxtecan.

Read more →📎 1 attachment
BSEBoard MeetingResults4 Aug 2026

AstraZeneca Pharma India Ltd

Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve This is to inform ....

AstraZeneca Pharma India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 to consider and approve the Un-audited Financial Results of the Company for the quarter ended June 30, 2026.

Read more →📎 1 attachment
Page 1 of 2Next →